Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

04:54 EDT 1st October 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

With First Trials On Horizon, Value Of Growing Philly Xarelto Claims Uncertain

It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases f...

Venous Thromboembolism therapeutics market set to hit $3.7 bn by 2025

Biospectrum Pradaxa, Xarelto, and Eliquis, which are all currently available, will see improved uptake over the forecas...

Portola's anticoagulant antidote gets EU review

Portola has said European regulators are to review its anticoagulant antidote, IndexXa (andexanet alfa), just days after the US regulator rejected the drug. California-based Portola said the Europea...

Bayer's Xarelto projected to become top-selling drug in Europe by 2022

Although Xarelto is an older drug, expanded indications and a new reversal agent could boost sales in Europe.Globally, however, the drug is predicted to fall well out of the top-ten drugs by sale...

Xarelto Clinical Trial Likened To 'Science Fair Project' By Philly Malpractice Lawyer

The quality and depth of clinical trials of the blood-thinner Xarelto could be a key issue when the first trials over the drug begin in Philadelphia courtrooms. With the first trial of more than 800 l...

Pradaxa dabigatran etexilate mesylate cardiovascular data

Real-world analysis shows Xarelto reduces ischemic stroke and intracranial hemorrhage versus warfarin

A retrospective database claims analysis found that adults with nonvalvular atrial fibrillation who received rivaroxaban (Xarelto) had a statistically significant 47 percent reduction in intracranial ...

Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin

New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart rhythm compared with Bristol-Myer Squibb’s (NYSE: BMY) Coum...

Matching PubMed Articles

Caution When Prescribing Xarelto to First-Time Patients.

Praxbind Available as Antidote to Bleeding from Pradaxa.

Pharmaceutical Approval Update.

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for ...

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy.

A 79-year-old woman was referred for rapid onset of painless bilateral vision loss. Anterior segment exams revealed bilateral spontaneous hyphema and fibrin accumulation. Observation of the posterior ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement